METHOD FOR PRODUCING ANTI-EGFR ANTIBODY, METHOD FOR IMPROVING AFFINITY FOR FcγRIIIa, AND ANTI-EGFR ANTIBODY

Modifying FR3 of anti-EGFR antibodies with arginine or aspartic acid residues enhances their affinity for FcγRIIIa, improving ADCC activity and cancer cell killing efficacy.

JP2024158328APending Publication Date: 2024-11-08SYSMEX CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023073449
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-27
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing anti-EGFR antibodies have suboptimal affinity for FcγRIIIa, limiting their effectiveness in antibody-dependent cellular cytotoxicity (ADCC) activity.

Method used

Modify at least three amino acid residues in the framework region 3 (FR3) of the light chain of anti-EGFR antibodies to arginine or aspartic acid residues, enhancing the antibody's affinity for FcγRIIIa.

Benefits of technology

Improves the affinity of anti-EGFR antibodies for FcγRIIIa, thereby increasing their ADCC activity and killing efficacy on target cells such as cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158328000001_ABST
    Figure 2024158328000001_ABST
Patent Text Reader

Abstract

To provide an anti-EGFR antibody with improved affinity for FcγRIIIa.SOLUTION: The foregoing problem is solved by modifying at least three amino acid residues in the framework region 3 of the light chain of an anti-EGFR antibody to arginine or aspartic acid residues.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing an anti-EGFR antibody, a method for improving the affinity of an anti-EGFR antibody for FcγRIIIa, and a method for improving the affinity of an anti-EGFR antibody for FcγRIIIa. [Background technology]

[0002] There are known techniques for modifying the amino acid sequence of an antibody to change the properties of the antibody. For example, Patent Document 1 describes that antibody aggregation is suppressed and antibody solubility and stability are increased by modifying framework region 2 (FR2) and framework region 3 (FR3) of the antibody. Patent Document 2 describes that antibody affinity is controlled by modifying FR3. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] US Patent Application Publication No. 2013 / 0303406 [Patent Document 2] US Patent Application Publication No. 2018 / 0179298 Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide an antibody that has improved affinity for FcγRIIIa by modifying an anti-EGFR antibody used as an anticancer agent, etc. Another object of the present invention is to provide a method for producing the antibody and a method for improving the affinity of an anti-EGFR antibody for FcγRIIIa. [Means for solving the problem]

[0005] The present inventors discovered that the affinity of an anti-EGFR antibody for FcγRIIIa can be improved by modifying at least three amino acid residues in the light chain FR3 of the anti-EGFR antibody to arginine residues or aspartic acid residues, and thus completed the present invention.

[0006] The present invention provides the following inventions [1] to

[17] . [1] A method for producing an anti-EGFR antibody, comprising the steps of generating an anti-EGFR antibody having an amino acid sequence using a polynucleotide encoding the amino acid sequence of the anti-EGFR antibody, and recovering the anti-EGFR antibody, wherein the anti-EGFR antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HCDR2 comprising the amino acid sequence SGG, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 2, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 3, an LCDR2 comprising the amino acid sequence YAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 4, wherein the anti-EGFR antibody comprises an amino acid sequence in which at least three amino acid residues in framework region 3 of the light chain are modified to arginine residues or aspartic acid residues, and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined by the Chothia method.

[0007] [2] A method for improving the affinity of an anti-EGFR antibody for FcγRIIIa, comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; an HCDR2 comprising the amino acid sequence SGG; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 2; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 3; an LCDR2 comprising the amino acid sequence YAS; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 4, by modifying at least three amino acid residues in framework region 3 of the light chain to arginine residues or aspartic acid residues, compared to before the modification, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined by the Chothia method.

[0008] [3] The method according to [1] or [2] above, wherein the at least three amino acid residues are at least three amino acid residues selected from the group consisting of amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

[0009] [4] The method according to any one of [1] to [3] above, wherein the at least three amino acid residues include the amino acid residues at positions 65, 67, and 70 of the light chain.

[0010] [5] The method according to any one of [1] to [3] above, wherein the at least three amino acid residues include the amino acid residues at positions 65, 67, 70 and 72 of the light chain.

[0011] [6] The method according to any one of [1] to [3] above, wherein the at least three amino acid residues include the amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

[0012] [7] The method according to any one of [1] to [6] above, wherein the heavy chain of the anti-EGFR antibody has the amino acid sequence of SEQ ID NO:5.

[0013] [8] The method according to any one of the above [1] to [3] or any one of the above [7] not citing [4] to [6], wherein the light chain of the anti-EGFR antibody comprises the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or the amino acid sequence of SEQ ID NO: 8.

[0014] [9] The method according to any one of [1] to [8] above, wherein the at least three amino acid residues are 3 to 5 amino acid residues.

[0015]

[10] An anti-EGFR antibody comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence SGG, an HCDR3 having the amino acid sequence of SEQ ID NO: 2, an LCDR1 having the amino acid sequence of SEQ ID NO: 3, an LCDR2 having the amino acid sequence YAS, and an LCDR3 having the amino acid sequence of SEQ ID NO: 4, wherein at least three amino acid residues in framework region 3 of the light chain are modified to arginine residues or aspartic acid residues, and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined by the Chothia method.

[0016]

[11] The antibody described in

[10] above, wherein the at least three amino acid residues are at least three amino acid residues selected from the group consisting of amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

[0017]

[12] The antibody described in

[10] or

[11] above, wherein the at least three amino acid residues include the amino acid residues at positions 65, 67 and 70 of the light chain.

[0018]

[13] The antibody described in

[10] or

[11] above, wherein the at least three amino acid residues include the amino acid residues at positions 65, 67, 70 and 72 of the light chain.

[0019]

[14] The antibody described in

[10] or

[11] above, wherein the at least three amino acid residues include amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

[0020]

[15] The antibody according to any one of

[10] to

[14] above, wherein the heavy chain has the amino acid sequence of SEQ ID NO:5.

[0021]

[16] The antibody described in any one of

[10] and

[11] above, or any one of

[15] not citing

[12] to

[14] above, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, or the amino acid sequence of SEQ ID NO: 8.

[0022]

[17] The antibody described in any one of

[10] to

[16] above, wherein the at least three amino acid residues are 3 to 5 amino acid residues. Effect of the Invention

[0023] EFFECTS OF THE PRESENT DISCLOSURE The present invention provides an anti-EGFR antibody with improved affinity for FcγRIIIa, a method for producing the antibody, and a method for improving the affinity of an anti-EGFR antibody for FcγRIIIa. [Brief description of the drawings]

[0024] [Figure 1] FIG. 1 shows the results of an example. [Diagram 2] FIG. 2 is an enlarged view of a portion of FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] (Anti-EGFR antibody) The anti-EGFR antibody of this embodiment is characterized in that at least three amino acid residues in FR3 of the light chain defined by the Chothia method are modified to arginine residues or aspartic acid residues. Here, an anti-EGFR antibody having the amino acid sequence before modification is called an "unmodified anti-EGFR antibody" or simply an "unmodified antibody". The at least three amino acid residues before modification are amino acid residues other than arginine residues and aspartic acid residues. This modification improves the affinity of the antibody to FcγRIIIa compared to before modification. This is expected to improve the antibody dependent cellular cytotoxicity (ADCC) activity of the anti-EGFR antibody.

[0026] A framework region (FR) is a region present in the variable regions of the light and heavy chains of an antibody, other than the complementarity determining region (CDR). Three CDRs are present in each of the variable regions of the light and heavy chains of an antibody, and constitute the antigen-binding site of the antibody. The three CDRs are called CDR1, CDR2, and CDR3, counting from the N-terminus of the antibody. In this specification, CDR1, CDR2, and CDR3 of the heavy chain are called HCDR1, HCDR2, and HCDR3, respectively, and CDR1, CDR2, and CDR3 of the light chain are called LCDR1, LCDR2, and LCDR3, respectively. FRs play the role of a scaffold connecting the three CDRs and contribute to the structural stability of the CDRs. FR3 is one of the FRs and refers to the region between CDR2 and CDR3.

[0027] The numbering method for the amino acid sequence of the antibody may be any known method. For example, the Chothia method (Chothia C. and Lesk AM., Canonical Structures for the Hypervariable Regions of Immunoglobulins., J Mol Biol., vol.196, p.901-917, 1987), the Kabat method (Kabat EA. et al., Sequences of Proteins of Immunological Interest., NIH publication No.91-3242), the IMGT method (Lefranc MP., IMGT Unique Numbering for the Variable (V), Constant (C), and Groove (G) Domains of IG, TR, MH, IgSF, and MhSF., Cold Spring Harb Protoc. 2011(6):633-642, 2011), Honergger method (Honegger A. et al., Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool., J Mol Biol., vol.309, p.657-670, 2001), the ABM method, the Contact method, etc. are known. In this specification, the numbering of the amino acid sequence of an anti-EGFR antibody is described according to the definition of the Chothia method. The CDR and FR in this specification are based on the Chothia method.

[0028] At least three modifications may be introduced into any position in the light chain FR3 of the anti-EGFR antibody. Preferably, the modifications are introduced into a region excluding amino acid residues that are folded inside the molecule and not exposed on the surface of the anti-EGFR antibody (hereinafter also referred to as "non-exposed residues"). The amino acid residues in the region excluding the non-exposed residues from the light chain FR3 are specifically amino acid residues at positions 57 to 81 of the light chain.

[0029] More preferably, the modification is introduced into the region excluding non-exposed residues and Vernier zone residues in the anti-EGFR antibody. Vernier zone residues are amino acid residues contained in FR that contribute to the structural stability of CDR. Therefore, it is preferable not to introduce modifications into Vernier zone residues. The amino acid residues in the region excluding non-exposed residues and Vernier zone residues from FR3 of the light chain are specifically the amino acid residues at positions 57-63, 65, 67, 70, and 72-81 of the light chain.

[0030] More preferably, the modification is introduced into amino acid residues whose side chains face the molecular surface among the amino acid residues in the region excluding non-exposed residues and Vernier zone residues in the anti-EGFR antibody. The modification of amino acid residues whose side chains face the molecular surface increases the contribution to the surface charge. Specifically, the amino acid residues whose side chains face the molecular surface in FR3 of the light chain are the amino acid residues at positions 57, 60, 63, 65, 67, 70, 72, 74, 76, 77, and 79 to 81 of the light chain. Among these, the positions 63, 65, 67, 70, and 72 of the light chain are particularly preferred as candidates for the introduction of the modification. In one example, three amino acid residues at positions 65, 67, and 70 of the light chain of the anti-EGFR antibody are modified. In another example, four amino acid residues at positions 65, 67, 70, and 72 of the light chain of the anti-EGFR antibody are modified. In yet another example, the anti-EGFR antibody has five altered amino acid residues at positions 63, 65, 67, 70, and 72 in the light chain.

[0031] The number of modifications introduced into FR3 is not particularly limited as long as it does not significantly impair the function of the anti-EGFR antibody, but is preferably 13 amino acids or less. That is, the number of modifications is specifically 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13. More preferably, the number of modifications is 5 or less.

[0032] The modification is a modification in which amino acid residues other than arginine residues and aspartic acid residues at the above-mentioned predetermined positions are changed to arginine residues or aspartic acid residues. The modification of amino acid residues introduced into the anti-EGFR antibody may be all to arginine residues, or all to aspartic acid residues. In addition, some of the modified positions may be changed to arginine residues, and the other positions may be changed to aspartic acid residues. That is, the modification may be at least three of the following modifications: a modification to an arginine residue or asparagine residue at position 63 of the light chain, a modification to an arginine residue or asparagine residue at position 65 of the light chain, a modification to an arginine residue or asparagine residue at position 67 of the light chain, a modification to an arginine residue or asparagine residue at position 70 of the light chain, and a modification to an arginine residue or asparagine residue at position 72 of the light chain. When three amino acid residues at positions 65, 67, and 70 of the light chain are modified, position 65 of the light chain is modified to an arginine or asparagine residue, position 67 of the light chain is modified to an arginine or asparagine residue, and position 70 of the light chain is modified to an arginine or asparagine residue. When four amino acid residues at positions 65, 67, 70, and 72 of the light chain are modified, position 65 of the light chain is modified to an arginine or asparagine residue, position 67 of the light chain is modified to an arginine or asparagine residue, position 70 of the light chain is modified to an arginine or asparagine residue, and position 72 of the light chain is modified to an arginine or asparagine residue. When the five amino acid residues at positions 63, 65, 67, 70, and 72 of the light chain are modified, position 63 of the light chain is modified to an arginine residue or an asparagine residue, position 65 of the light chain is modified to an arginine residue or an asparagine residue, position 67 of the light chain is modified to an arginine residue or an asparagine residue, position 70 of the light chain is modified to an arginine residue or an asparagine residue, and position 72 of the light chain is modified to an arginine residue or an asparagine residue.

[0033] The anti-EGFR antibody comprises HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, HCDR2 comprising the amino acid sequence SGG, HCDR3 comprising the amino acid sequence of SEQ ID NO: 2, LCDR1 comprising the amino acid sequence of SEQ ID NO: 3, LCDR2 comprising the amino acid sequence YAS, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 4. The sequences of each CDR are described below.

[0034] HCDR1: SEQ ID NO: 1 GFSLTNY

[0035] HCDR2: SGG

[0036] HCDR3: SEQ ID NO:2 LTYYDYEFA

[0037] LCDR1: SEQ ID NO:3 SQSIGTN

[0038] LCDR2: YAS

[0039] LCDR3: SEQ ID NO: 4 NNNWPT

[0040] Preferably, the amino acid sequence of the heavy chain of the anti-EGFR antibody comprises the amino acid sequence of SEQ ID NO:5.

[0041] SEQ ID NO:5 QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQG TLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0042] The heavy chain of the anti-EGFR antibody may be modified as long as the modification does not result in loss of ADCC activity (ADCC activity is described below) from the anti-EGFR antibody.

[0043] As described above, the modified anti-EGFR antibody has improved affinity for FcγRIIIa compared to the unmodified anti-EGFR antibody. "Improved affinity" means that the affinity between the anti-EGFR antibody and FcγRIIIa is stronger. The affinity between the anti-EGFR antibody and FcγRIIIa can be evaluated by known methods. For example, it can be confirmed by subjecting the anti-EGFR antibody to an affinity column using FcγRIIIa as a ligand and measuring the elution time (retention time). A longer elution time of the anti-EGFR antibody subjected to the affinity column is an indicator of improved affinity. An example of an affinity column is TSKgel (registered trademark) FcR-IIIA-NPR (manufactured by Tosoh Corporation). The affinity for FcγRIIIa may be evaluated by kinetic parameters in an antigen-antibody reaction, or by immunological measurement such as ELISA. Kinetic parameters include the binding rate constant (k on ), dissociation rate constant (k off ) and dissociation constant (K D For example, a lower dissociation constant is an indicator of improved affinity. An example of an affinity indicator based on immunological measurements is the 50% effective concentration (EC50). Kinetic parameters in antigen-antibody reactions can be obtained by surface plasmon resonance (SPR) technology.

[0044] It is believed that the ADCC activity is improved by improving the affinity for FcγRIIIa. ADCC refers to a reaction in which an antibody bound to an antigen on the surface of a target cell (e.g., a tumor cell) in vivo activates an effector cell through binding between the Fc region of the antibody and the Fc receptor of the effector cell, such as a natural killer cell or an eosinophil, thereby killing the target cell. It is believed that the ADCC activity is improved by improving the affinity for FcγRIIIa, and the killing effect on the target cell (e.g., a cancer cell) can be improved. The ADCC activity can be evaluated using a known method, for example, by mixing and incubating effector cells, tumor cells, and an antibody, and measuring the number of killed tumor cells.

[0045] The light chain of the anti-EGFR antibody containing the above-mentioned amino acid residue modification includes, for example, the amino acid sequence of SEQ ID NO: 6, 7, or 8. SEQ ID NO: 6 is the sequence of the light chain of the anti-EGFR antibody, and is an amino acid sequence in which the amino acid residues at positions 65, 67, and 70 of the light chain are replaced with arginine residues compared to the unmodified antibody. SEQ ID NO: 7 is the sequence of the light chain of the anti-EGFR antibody, and is an amino acid sequence in which the amino acid residues at positions 65, 67, 70, and 72 of the light chain are replaced with arginine residues compared to the unmodified antibody. SEQ ID NO: 8 is the sequence of the light chain of the anti-EGFR antibody, and is an amino acid sequence in which the amino acid residues at positions 63, 65, 67, 70, and 72 of the light chain are replaced with aspartic acid residues compared to the unmodified antibody. These amino acid sequences are shown below. The arginine and aspartic acid residues introduced by modification are underlined.

[0046] SEQ ID NO:6 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG R G R GT R FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0047] SEQ ID NO:7 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG R G R GT R F RLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0048] SEQ ID NO:8 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRF D G D G D GT D F D LSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0049] The anti-EGFR antibody may be an antibody derived from any animal, for example, an antibody derived from a human, a mouse, a rat, a hamster, a rabbit, a goat, a horse, a chicken, etc. The anti-EGFR antibody may be a chimeric antibody, a humanized antibody, or a human antibody. The chimeric antibody is preferably a chimeric antibody between a human and a non-human animal, more preferably a chimeric antibody between a human and a mouse. The class of the anti-EGFR antibody may be any of IgG, IgA, IgM, IgD, and IgE, and is preferably IgG. In addition to the modification introduced for the purpose of improving affinity with FcγRIIIa, the anti-EGFR antibody may have amino acid residues modified for another purpose. For example, modifications to improve affinity with an antigen, modifications to improve affinity with FcRn, modifications to suppress antibody aggregation, modifications to improve antibody solubility, modifications to improve antibody thermal stability, etc. may be mentioned.

[0050] The modified anti-EGFR antibody can be used in the same manner as the unmodified antibody, for example, as an active ingredient of an anticancer drug.

[0051] (Method for producing anti-EGFR antibodies) The present embodiment relates to a method for producing the above-mentioned anti-EGFR antibody (hereinafter also simply referred to as a production method).

[0052] The production method includes a step of producing an anti-EGFR antibody and a step of recovering the anti-EGFR antibody. Specifically, a polynucleotide encoding the amino acid sequence of a modified anti-EGFR antibody is prepared. Then, the modified antibody is produced and recovered using the polynucleotide by a protein expression system. The protein expression system may be an expression system using a host cell, or may be a cell-free protein synthesis system. Examples of host cells include mammalian cells, insect cells, Escherichia coli, and yeast. Examples of cell-free protein synthesis systems include a wheat germ-derived synthesis system, an Escherichia coli-derived synthesis system, and a reconstituted cell-free protein synthesis system.

[0053] An example of a method for producing a polynucleotide encoding a modified anti-EGFR antibody is as follows. First, an amino acid residue modification is introduced into an unmodified EGFR antibody by a known molecular biology technique such as DNA recombination technology. For example, when a hybridoma that produces an unmodified EGFR antibody is available, a polynucleotide encoding a light chain and a polynucleotide encoding a heavy chain are each synthesized by reverse transcription and RACE (Rapid Amplification of cDNA ends) using RNA extracted from the hybridoma. A polynucleotide encoding a light chain among the polynucleotides is amplified by PCR using a primer for introducing modifications into at least three amino acid residues in FR3 of the light chain, thereby obtaining a polynucleotide encoding a light chain with modifications introduced into FR3.

[0054] An example of anti-EGFR antibody production using a host cell is as follows. First, each of the above polynucleotides is incorporated into an expression vector known in the art to obtain an expression vector containing a polynucleotide encoding an antibody in which FR3 of the light chain has been modified. The polynucleotide encoding the light chain and the polynucleotide encoding the heavy chain may be incorporated into one expression vector, or may be incorporated separately into two expression vectors. The type of expression vector is not particularly limited, and may be an expression vector for mammalian cells or an expression vector for E. coli. The obtained expression vector is introduced (transfected or transformed) into a suitable host cell (e.g., mammalian cell or E. coli) and expressed in the host cell to produce a modified anti-EGFR antibody. Next, the host cell is dissolved in a solution containing a suitable solubilizing agent to release the anti-EGFR antibody into the solution. If the host cell secretes the modified anti-EGFR antibody into the medium, the culture supernatant is collected.

[0055] Once a stable line of host cells into which an expression vector has been introduced has been established, the cells can be cultured under appropriate conditions to produce an antibody, unless the cells die. Alternatively, an expression vector incorporating a polynucleotide encoding an antibody can be stored and, if necessary, introduced into a host cell to produce and recover the antibody. The expression vector can be stored by freezing and storing a solution containing the polynucleotide, which is the expression vector, or cells containing the expression vector.

[0056] When obtaining an antibody using a cell-free protein synthesis system, a polynucleotide encoding a light chain with a modified FR3 and a polynucleotide encoding a heavy chain of an unmodified anti-EGFR antibody are added to a cell-free protein synthesis system and incubated under appropriate conditions to produce and recover the modified antibody.

[0057] The antibody can be collected by a known method such as affinity chromatography. If necessary, the collected antibody may be purified by a known method such as gel filtration.

[0058] (Method for improving affinity of anti-EGFR antibody for FcγRIIIa) The present embodiment relates to a method for improving the affinity of an anti-EGFR antibody for FcγRIIIa. By modifying at least three amino acid residues in FR3 of an unmodified EGFR antibody to arginine residues or aspartic acid residues, the affinity of the anti-EGFR antibody for FcγRIIIa can be improved. The modified anti-EGFR antibody is as described above.

[0059] Whether or not the affinity of an anti-EGFR antibody for FcγRIIIa has been improved can be confirmed, for example, by subjecting the anti-EGFR antibody to an affinity column with FcγRIIIa as a ligand and measuring the elution time. Alternatively, it can also be evaluated by kinetic parameters in an antigen-antibody reaction or immunological measurement methods such as ELISA. Kinetic parameters include the binding rate constant (k on ), dissociation rate constant (k off ) and dissociation constant (K D ), preferably K D An example of an indicator of affinity determined by immunological measurement is the 50% effective concentration (EC50). Alternatively, affinity can be evaluated by measuring the ADCC activity of an anti-EGFR antibody against FcγRIIIa.

[0060] When the affinity of anti-EGFR antibodies for FcγRIIIa is improved, the K D The value is, for example, about 1 / 2, about 1 / 5, about 1 / 10, about 1 / 20, about 1 / 50, about 1 / 100, or about 1 / 1000 compared to an unmodified antibody.

[0061] (Method for improving ADCC activity of anti-EGFR antibody) The present embodiment relates to a method for improving the ADCC activity of an anti-EGFR antibody comprising an HCDR1 comprising the amino acid sequence of SGG, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 2, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 3, an LCDR2 comprising the amino acid sequence of YAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 4, by modifying at least three amino acid residues of FR3 to arginine residues or aspartic acid residues in an unmodified EGFR antibody, thereby improving the affinity of the anti-EGFR antibody to FcγRIIIa. This can improve the ADCC activity of the anti-EGFR antibody. The modified anti-EGFR antibody is as described above.

[0062] (Polynucleotide) The present embodiment relates to a polynucleotide encoding a modified anti-EGFR antibody. The polynucleotide may be incorporated into a suitable vector.

[0063] (host cell) This embodiment relates to a host cell containing the above-mentioned vector. The type of host cell is not particularly limited, and may be a eukaryotic cell, a prokaryotic cell, etc. As the eukaryotic cell, an animal cell is preferable, and a mammalian cell is more preferable.

[0064] Pharmaceutical Composition The present embodiment relates to a pharmaceutical composition comprising a modified anti-EGFR antibody. The pharmaceutical composition may contain components other than the modified anti-EGFR antibody. The pharmaceutical composition preferably contains a pharmacologically effective amount of the anti-EGFR antibody.

[0065] The pharmaceutical composition may contain a pharma- ceutically acceptable additive. Such additives can be appropriately selected from additives known in the art. Examples of known additives include excipients, lubricants, binders, disintegrants, coating agents, capsule bases, plasticizers, colorants, solvents, stabilizers, preservatives, buffers, soothing agents, bases, emulsifiers, suspending agents, flavoring agents, sweeteners, adsorbents, solubilizing agents, pH regulators, thickeners, isotonic agents, dispersants, preservatives, wetting agents, flavoring agents, antioxidants, etc.

[0066] The formulation of the pharmaceutical composition is not particularly limited, and may be any formulation known to those skilled in the art, such as a solid formulation, a semi-solid formulation, a liquid formulation, an injection, a suppository, etc. Specific dosage forms include, but are not limited to, injections, liquids, etc.

[0067] The modified anti-EGFR antibodies can be suitably used to treat various tumors, including, but not limited to, colorectal cancer, colon cancer, rectal cancer, head and neck cancer, pharyngeal cancer, oral cancer, laryngeal cancer, pancreatic cancer, lung cancer, breast cancer, and the like.

[0068] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. EXAMPLES

[0069] Example: Obtaining anti-EGFR antibodies and measuring FcγRIIIa binding affinity Anti-EGFR antibodies with modified FR3 were generated and their FcγRIIIa binding affinity was measured.

[0070] (Obtaining anti-EGFR antibodies) Three types of modified antibodies (hereinafter, each modified antibody is referred to as R3, R4, and D5) were obtained by modifying FR3 of the light chain of an anti-EGFR antibody.

[0071] Polynucleotides encoding the amino acid sequences of SEQ ID NOs: 6, 7, and 8 were prepared. Each polynucleotide was incorporated into a plasmid, and the plasmid was transfected into Expi293 cells. Culture supernatants were collected from the cells expressing the anti-EGFR modified antibodies, and the expressed anti-EGFR modified antibodies were purified from the culture supernatants to obtain each anti-EGFR modified antibody.

[0072] These modified antibodies contained modifications of amino acid residues in FR3 of the light chain compared to FR3 of the unmodified anti-EGFR antibody. Specifically, R3 (SEQ ID NO: 6) contained modifications to arginine residues at positions 65, 67, and 70 of the light chain, R4 (SEQ ID NO: 7) contained modifications to arginine residues at positions 65, 67, 70, and 72 of the light chain, and D5 (SEQ ID NO: 8) contained modifications to aspartic acid at positions 63, 65, 67, 70, and 72 of the light chain. All of these amino acid residue modifications were substitutions.

[0073] R3 light chain: SEQ ID NO:6 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG R G R GT R FTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0074] R4 light chain: SEQ ID NO: 7 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG R G R GT R F RLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0075] D5 light chain: SEQ ID NO:8 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRF D G D G D GT D F D LSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0076] The amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and the heavy chain of these modified antibodies were as follows:

[0077] HCDR1: SEQ ID NO: 1 GFSLTNY

[0078] HCDR2: SGG

[0079] HCDR3: SEQ ID NO:2 LTYYDYEFA

[0080] LCDR1: SEQ ID NO:3 SQSIGTN

[0081] LCDR2: Y.A.S.

[0082] LCDR3: SEQ ID NO: 4 NNNWPT

[0083] Heavy chain: SEQ ID NO:5 QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQG TLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0084] The sequence of the light chain of the unmodified anti-EGFR antibody was as shown in SEQ ID NO:9.

[0085] Light chain of unmodified anti-EGFR antibody: SEQ ID NO: 9 DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0086] The FcγRIIIa binding affinity of these modified antibodies and the unmodified anti-EGFR antibody was confirmed. To confirm the FcγRIIIa binding affinity, an affinity chromatography column, TSKgel (registered trademark) FcR-IIIA-NPR (manufactured by Tosoh Corporation), was used. This column was capable of separating antibodies based on their binding affinity to FcγRIIIa. The analysis conditions were as follows.

[0087] [Table 1]

[0088] [Table 2]

[0089] Each anti-EGFR modified antibody was applied to the column under the above-mentioned conditions, and the elution time of the antibody from the column was measured. The results are shown in Figure 1. The vertical axis of Figure 1 is the absorbance at 280 nm, and the horizontal axis is the elution time. Figure 2 is an enlarged view of Figure 1, including the strongest peak of each graph. In the figure, "WT" represents the unmodified antibody. Figures 1 and 2 show that the elution peak of the modified antibody is shifted to the right compared to the elution peak of the unmodified antibody, and the elution time is delayed. By introducing an arginine or aspartic acid residue modification into the light chain of FR3, the affinity of the anti-EGFR antibody to FcγRIIIa could be improved.

Claims

1. The method includes the steps of: producing an anti-EGFR antibody having an amino acid sequence of an anti-EGFR antibody using a polynucleotide encoding the amino acid sequence of the anti-EGFR antibody; and recovering the anti-EGFR antibody. the anti-EGFR antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HCDR2 comprising the amino acid sequence SGG, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 2, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 3, an LCDR2 comprising the amino acid sequence YAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 4; the anti-EGFR antibody comprises an amino acid sequence in which at least three amino acid residues in framework region 3 of the light chain are modified to arginine residues or aspartic acid residues; wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined according to the Chothia method; Method for producing anti-EGFR antibodies.

2. A method for improving the affinity for FcγRIIIa of an anti-EGFR antibody comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence SGG, an HCDR3 having the amino acid sequence of SEQ ID NO: 2, an LCDR1 having the amino acid sequence of SEQ ID NO: 3, an LCDR2 having the amino acid sequence YAS, and an LCDR3 having the amino acid sequence of SEQ ID NO: 4, by modifying at least three amino acid residues in framework region 3 of the light chain to arginine residues or aspartic acid residues, compared to before the modification, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined by the Chothia method.

3. 3. The method of claim 1 or 2, wherein the at least three amino acid residues are at least three amino acid residues selected from the group consisting of amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

4. 3. The method of claim 1 or 2, wherein the at least three amino acid residues include amino acid residues at positions 65, 67 and 70 of the light chain.

5. 3. The method of claim 1 or 2, wherein the at least three amino acid residues include amino acid residues at positions 65, 67, 70 and 72 of the light chain.

6. 3. The method of claim 1 or 2, wherein the at least three amino acid residues include amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

7. The method of claim 1 or 2, wherein the heavy chain of the anti-EGFR antibody has the amino acid sequence of SEQ ID NO:

5.

8. The method of claim 1 or 2, wherein the light chain of the anti-EGFR antibody comprises the amino acid sequence of SEQ ID NO:6, the amino acid sequence of SEQ ID NO:7, or the amino acid sequence of SEQ ID NO:

8.

9. The method according to claim 1 or 2, wherein the at least three amino acid residues are between 3 and 5 amino acid residues.

10. An anti-EGFR antibody comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence SGG, an HCDR3 having the amino acid sequence of SEQ ID NO: 2, an LCDR1 having the amino acid sequence of SEQ ID NO: 3, an LCDR2 having the amino acid sequence YAS, and an LCDR3 having the amino acid sequence of SEQ ID NO: 4, wherein at least three amino acid residues in framework region 3 of the light chain are modified to arginine residues or aspartic acid residues, and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 and framework region 3 are defined by the Chothia method.

11. The antibody of claim 10, wherein the at least three amino acid residues are at least three amino acid residues selected from the group consisting of amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

12. The antibody of claim 10, wherein the at least three amino acid residues include amino acid residues 65, 67 and 70 of the light chain.

13. The antibody of claim 10, wherein the at least three amino acid residues include amino acid residues at positions 65, 67, 70 and 72 of the light chain.

14. The antibody of claim 10, wherein the at least three amino acid residues include amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

15. The antibody of claim 10, wherein the heavy chain has the amino acid sequence of SEQ ID NO:

5.

16. The antibody of claim 10, wherein the light chain comprises the amino acid sequence of SEQ ID NO:6, the amino acid sequence of SEQ ID NO:7, or the amino acid sequence of SEQ ID NO:

8.

17. The antibody described in claim 10, wherein the at least three amino acid residues are 3 to 5 amino acid residues.

Citation Information

Patent Citations

  • Engineering of immunoglobulin domains

    US20130303406A1

  • Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method

    US20180179298A1